LONDON – Pharmaceutical AstraZeneca began trials with a new antibody-based drug for the treatment and prevention of Covid-19.
The laboratory said today that the test will evaluate the safety and tolerance of a drug called AZD7442 that combines two monoclonal antibodies, proteins of the immune system created in the laboratory that seek to mimic natural antibodies. The drug was created by Vanderbilt University Medical Center in Nashville, Tennessee.
It is the first time that AZD7442 has been used in humans; the test will be done with 48 adults in the UK. If it is safe, there will be further evidence of its efficacy for the treatment and prevention of Covid-19.
“This combination of antibodies, coupled with our proprietary half-life extension technology has the potential to improve both efficacy and durability of use in addition to reducing the likelihood of viral resistance, said Mene Pangalos, executive vice president of biopharmaceutical research at AstraZeneca.
Antibody-based treatment of patients who recovered from Covid-19.